(NASDAQ: FENC) Fennec Pharmaceuticals's forecast annual revenue growth rate of 65.54% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.5%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.08%.
Fennec Pharmaceuticals's revenue in 2024 is $21,252,000.On average, 3 Wall Street analysts forecast FENC's revenue for 2024 to be $1,333,938,771, with the lowest FENC revenue forecast at $1,190,498,958, and the highest FENC revenue forecast at $1,474,234,995. On average, 3 Wall Street analysts forecast FENC's revenue for 2025 to be $1,792,198,216, with the lowest FENC revenue forecast at $1,450,658,075, and the highest FENC revenue forecast at $1,989,133,247.
In 2026, FENC is forecast to generate $2,721,237,262 in revenue, with the lowest revenue forecast at $2,333,031,080 and the highest revenue forecast at $3,109,443,444.